GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » MiMedx Group Inc (NAS:MDXG) » Definitions » Cash Flow from Operations

MiMedx Group (MiMedx Group) Cash Flow from Operations : $26.8 Mil (TTM As of Dec. 2023)


View and export this data going back to 2008. Start your Free Trial

What is MiMedx Group Cash Flow from Operations?

Cash flow from operations refers to the cash brought in through a company's normal business operations. It is the cash flow before any investment or financing activities. It is the cash version of net income.

For the three months ended in Dec. 2023, MiMedx Group's Net Income From Continuing Operations was $62.7 Mil. Its Depreciation, Depletion and Amortization was $0.8 Mil. Its Change In Working Capital was $-10.1 Mil. Its cash flow from deferred tax was $0.0 Mil. Its Cash from Discontinued Operating Activities was $0.0 Mil. Its Asset Impairment Charge was $-1.8 Mil. Its Stock Based Compensation was $4.2 Mil. And its Cash Flow from Others was $-45.5 Mil. In all, MiMedx Group's Cash Flow from Operations for the three months ended in Dec. 2023 was $10.3 Mil.


MiMedx Group Cash Flow from Operations Historical Data

The historical data trend for MiMedx Group's Cash Flow from Operations can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

MiMedx Group Cash Flow from Operations Chart

MiMedx Group Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cash Flow from Operations
Get a 7-Day Free Trial Premium Member Only Premium Member Only -39.41 -30.26 -1.98 -17.89 26.78

MiMedx Group Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Cash Flow from Operations Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -5.62 -4.05 7.78 12.79 10.26

MiMedx Group Cash Flow from Operations Calculation

Cash flow from operations refers to the cash brought in through a company's normal business operations. It is the cash flow before any investment or financing activities. It is the cash version of net income.

MiMedx Group's Cash Flow from Operations for the fiscal year that ended in Dec. 2023 is calculated as:

MiMedx Group's Cash Flow from Operations for the quarter that ended in Dec. 2023 is:


Cash Flow from Operations for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $26.8 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


MiMedx Group  (NAS:MDXG) Cash Flow from Operations Explanation

For companies reported in indirect method, cash flow from operations contains six items:

1. Net Income From Continuing Operations:
Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. It excludes extraordinary items, income from the cumulative effects of accounting changes, non-recurring items, income from tax loss carry forward, and preferred dividends.

MiMedx Group's net income from continuing operations for the three months ended in Dec. 2023 was $62.7 Mil.

2. Depreciation, Depletion and Amortization:
Depreciation is a present expense that accounts for the past cost of an asset that is now providing benefits.
Depletion and amortization are synonyms for depreciation.
Generally:
The term depreciation is used when discussing man made tangible assets
The term depletion is used when discussing natural tangible assets
The term amortization is used when discussing intangible assets

MiMedx Group's depreciation, depletion and amortization for the three months ended in Dec. 2023 was $0.8 Mil.

3. Change In Working Capital:
Working Capital is a measure of a company's short term liquidity or its ability to cover short term liabilities. It is defined as the difference between a company's current assets and current liabilities. Changes in Working Capital is reported in the cash flow statement since it is one of the major ways in which net income can differ from operating cash flow.

MiMedx Group's change in working capital for the three months ended in Dec. 2023 was $-10.1 Mil. It means MiMedx Group's working capital declined by $10.1 Mil from Sep. 2023 to Dec. 2023 .

4. Deferred Tax:
It is the cash flow generated from deferred tax.

MiMedx Group's cash flow from deferred tax for the three months ended in Dec. 2023 was $0.0 Mil.

5. Cash from Discontinued Operating Activities:
Net cash from all of the entity's discontinued operating activities.

MiMedx Group's cash from discontinued operating Activities for the three months ended in Dec. 2023 was $0.0 Mil.

6. Asset Impairment Charge:
It is the charge against earnings resulting from the aggregate write down of all assets from their carrying value to their fair value.

MiMedx Group's asset impairment charge for the three months ended in Dec. 2023 was $-1.8 Mil.

7. Stock Based Compensation:
It is a way corporations use stock options to reward employees. It provides executives and employees the opportunity to share in the growth of the company and, if structured properly, can align their interests with the interests of the company's shareholders and investors, without burning the company's cash on hand.

MiMedx Group's stock based compensation for the three months ended in Dec. 2023 was $4.2 Mil.

8. Cash Flow from Others:
These are cash differences caused by the change of inventory, accounts payable, accounts receivable etc. For instance, if a company pays its suppliers slower, its cash position will build up faster. If a company receives payments from its customers slower, its account receivables will rise, and its cash position will grow more slowly (or even shrink).

MiMedx Group's cash flow from others for the three months ended in Dec. 2023 was $-45.5 Mil.


MiMedx Group Cash Flow from Operations Related Terms

Thank you for viewing the detailed overview of MiMedx Group's Cash Flow from Operations provided by GuruFocus.com. Please click on the following links to see related term pages.


MiMedx Group (MiMedx Group) Business Description

Traded in Other Exchanges
N/A
Address
1775 West Oak Commons Court, NE, Marietta, GA, USA, 30062
MiMedx Group Inc develops and markets regenerative biomaterial products and bioimplants made from the human amniotic membrane, birth tissues, and human skin & bone. Its products are primarily targeted towards the wound-care, burn, surgical, sports medicine, and orthopedics markets. MiMedx's key products are allografts processed from amniotic tissue, which include EpiFix for external use and AmnioFix for internal use. AmnioCord, AmnioFill, EpiBurn, and EpiCord are some of its other products. Also, MiMedx sells allografts for ophthalmic surgery and dental applications through licenses to third parties.
Executives
Rice Doug officer: Chief Financial Officer 3451 PLANO PARKWAY, LEWISVILLE TX 75056
Joseph H Capper officer: Chief Executive Officer BIOTELEMETRY, INC., 1000 CEDAR HOLLOW ROAD, #102, MALVERN PA 19355
Robert Benjamin Stein officer: EVP, Research and Development C/O AGENUS INC., 3 FORBES ROAD, LEXINGTON MA 02421
Peter M Carlson officer: Chief Financial Officer BRIGHTHOUSE FINANCIAL, INC., 11225 NORTH COMMUNITY HOUSE ROAD, CHARLOTTE NC 28277
William Lawrence Phelan officer: Chief Accounting Officer 1775 WEST OAK COMMONS COURT NE, MARIETTA GA 30062
Hulse William Frank Iv officer: General Counsel 1775 WEST OAK COMMONS COURT NE, MARIETTA GA 30062
Ricci S Whitlow officer: Chief Operating Officer C/O CATALENT, INC., 14 SCHOOLHOUSE ROAD, SOMERSET NJ 08873
Rohit Kashyap officer: EVP & Chief Commercial Officer 8023 VANTAGE DRIVE, SAN ANTONIO TX 78230
Timothy R Wright director, officer: Chief Executive Officer C/O CURAXIS, 1004 CHAGFORD WAY, RALEIGH NC 27614
Mark Graves officer: SVP & Chief Compliance Officer 1775 WEST OAK COMMONS COURT, MARIETTA GA 30062
Scott M Turner officer: SVP, Operations & Procurement 1775 WEST OAK COMMONS COURT, MARIETTA GA 30062
Phyllis Gardner director 618 MIRADA AVENUE, STANFORD CA 94305
Michael J Giuliani director 1775 WEST OAK COMMONS COURT NE, MARIETTA GA 30062
Cato T Laurencin director C/O UNIVERSITY OF CONNECTICUT, 263 FARMINGTON AVENUE, FARMINGTON CT 06030-3800
William A Hawkins director MEDTRONIC INC, 710 MEDTRONIC PKWY, MS LC310, MINNEAPOLIS MN 55432-5604